Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.

Kharenko OA, Patel RG, Brown SD, Calosing C, White A, Lakshminarasimhan D, Suto RK, Duffy BC, Kitchen DB, McLure KG, Hansen HC, van der Horst EH, Young PR.

J Med Chem. 2018 Sep 27;61(18):8202-8211. doi: 10.1021/acs.jmedchem.8b00666. Epub 2018 Sep 13.

PMID:
30165024
2.

CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.

Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T.

Cancer Cell. 2016 Nov 14;30(5):792-805. doi: 10.1016/j.ccell.2016.10.003. Epub 2016 Oct 27.

3.

Prevesical Calcification and Hydronephrosis in a Girl Treated for Vesicoureteral Reflux.

Kuipers S, van der Horst EH, Verbeke JI, Bökenkamp A.

Glob Pediatr Health. 2016 Jun 13;3:2333794X16652272. doi: 10.1177/2333794X16652272. eCollection 2016.

4.

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY.

Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2.

PMID:
26393951
5.

A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.

Kim SY, Theunissen JW, Balibalos J, Liao-Chan S, Babcock MC, Wong T, Cairns B, Gonzalez D, van der Horst EH, Perez M, Levashova Z, Chinn L, D'Alessio JA, Flory M, Bermudez A, Jackson DY, Ha E, Monteon J, Bruhns MF, Chen G, Migone TS.

Blood Cancer J. 2015 May 29;5:e316. doi: 10.1038/bcj.2015.39.

6.

Introducing the HOPE (Hypospadias Objective Penile Evaluation)-score: a validation study of an objective scoring system for evaluating cosmetic appearance in hypospadias patients.

van der Toorn F, de Jong TP, de Gier RP, Callewaert PR, van der Horst EH, Steffens MG, Hoebeke P, Nijman RJ, Bush NC, Wolffenbuttel KP, van den Heijkant MM, van Capelle JW, Wildhagen M, Timman R, van Busschbach JJ.

J Pediatr Urol. 2013 Dec;9(6 Pt B):1006-16. doi: 10.1016/j.jpurol.2013.01.015. Epub 2013 Mar 11.

PMID:
23491983
7.

Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK.

Neoplasia. 2009 Apr;11(4):355-64.

8.

HER3 is a determinant for poor prognosis in melanoma.

Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A.

Clin Cancer Res. 2008 Aug 15;14(16):5188-97. doi: 10.1158/1078-0432.CCR-08-0186.

9.

The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.

van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, Wesche H.

Neoplasia. 2008 Apr;10(4):340-7.

10.

Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1.

van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See LH, Nguyen KQ, Hoey T, Wesche H, Powers S.

Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6. Epub 2005 Oct 24.

11.

Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies.

van der Horst EH, Murgia M, Treder M, Ullrich A.

Int J Cancer. 2005 Jul 1;115(4):519-27.

12.

TaqMan-based quantification of invasive cells in the chick embryo metastasis assay.

van der Horst EH, Leupold JH, Schubbert R, Ullrich A, Allgayer H.

Biotechniques. 2004 Dec;37(6):940-2, 944, 946.

13.

Supplemental Content

Loading ...
Support Center